UK: Cannabis In The UK – A Regulatory Environment In Transition?

Recently, three British MPs went to Canada on a fact-finding cross-party trip to consider the effects of a more relaxed regulatory environment in respect of cannabis. After the trip, the MPs predicted that the UK would follow Canada's lead and legalise cannabis for adult use within a decade.

The recent trend towards decriminalization of cannabis in other countries suggests they may be right, but in the meantime, a proliferation of products containing extracts from cannabis plants are appearing in UK stores. This Client Alert sets out the current rules regarding the regulation of cannabis products and medicinal cannabis in the UK.

What substances are at issue?

Cannabinoids are the chemical substances found in cannabis. Over 100 different cannabinoids have been linked to the cannabis plant. The two that are most relevant to the ongoing medical and legalisation debate are cannabidiol (CBD) and tetrahydrocannabinol (THC). The key difference between CBD and THC is that THC has psychoactive properties, meaning users experience a high from its use, whereas CBD has no psychoactive properties (it contains little or no THC).

What is the relevant legislation?

The main relevant UK legislation is the Misuse of Drugs Act 1971 (the Act) and the Misuse of Drugs Regulations 2001 (as amended by the Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018) (the Regulations).

In the UK cannabis, cannabinol and cannabinol derivatives are classified as Class B drugs under Schedule 2 of the Act; as such, they are controlled drugs. Cannabinol derivatives include tetrahydro derivatives. THC, a tetrahydro derivative of cannabinol, is a controlled drug under the Act. CBD is not listed in any schedule of the Act and so is not, of itself, a controlled drug.

The Regulations set out how controlled drugs can be used legally for legitimate purposes and the various restrictions on import, export, production, possession and supply that apply, as well as the different labelling, record-keeping, destruction and safety requirements that are applicable based on the schedule to the Regulations that governs the controlled drug. Cannabis, cannabinol and cannabinol derivatives are included in Schedule 1 of the Regulations; therefore, they are subject to Schedule 1 restrictions. CBD is not listed in any of the schedules of the Regulations, so it is not controlled by the Regulations.

After a review of cannabis regulation in the UK announced by the Home Secretary last year (prompted by the cases of two children who had been denied access to cannabis oil to control their epileptic seizures), the Regulations were amended in November, 2018 to create a new category of generally unlicensed cannabis-based products – called “cannabis-based product for medicinal use in humans” (CBPM) in order to allow unlicensed cannabis-based products to be prescribed for medicinal purposes, provided certain requirements are met.

Restrictions and licensing requirements

In order to legally produce, possess, supply, cultivate, import or export cannabis products, there are various regulatory requirements that must be met, depending on whether the product contains a controlled drug or is classified as a CBPM. It is important to remember that even if the end product is an exempt product or a CBPM, it is still an offence under the Act to cultivate the cannabis plant without a Home Office cultivation licence, which will be granted only if certain conditions are met.

THC

Because THC is a controlled drug, products that contain THC are subject to strict legislative controls. For example, section 3(1) of the Act prohibits the importation and exportation of controlled drugs; section 4(1) makes it unlawful to produce, supply or offer to supply a controlled drug; and section 5(1) makes it unlawful to be in possession of a controlled drug. The Regulations provide that the restrictions in the Act on importation, exportation, production, supply and possession do not apply to substances that qualify as “exempt products”.  Under the Regulations, an “exempt product” is a preparation or other product containing a controlled drug where “(a) the preparation or other product is not designed for administration of the controlled drug to a human being or animal; (b) the controlled drug in any component part is packaged in such a form, or in combination with other active or inert substances in such a manner, that it cannot be recovered by readily applicable means or in a yield which constitutes a risk to health; and (c) no one component part of the product or preparation contains more than one milligram of the controlled drug…”. The meaning of “exempt product” is not wholly clear, but the Advisory Council on the Misuse of Drugs, a public advisory body, suggests that the exempt product definition is intended to relate to small quantities of controlled substances which are in a non-recoverable form and are not for human [or animal] administration. The exempt product exception is therefore likely to have limited applicability to products containing THC that are currently being sold in UK shops.

CBD

Pure CBD is not a controlled drug under the Act or the Regulations. However, the Home Office’s position appears to be that it is very difficult to isolate pure CBD and remove any controlled cannabinoids, such as THC (despite the fact that there are producers who unequivocally say they can do so) and the presence of THC (even in very small quantities) is highly likely to mean that CBD products intended for human or animal administration are controlled under both the Act and the Regulations. Thus, the Home Office’s approach seems to be that a Home Office licence would be required to import, export, produce, supply or possess CBD products. Nevertheless, products advertised as containing CBD are widely available in the UK, and there is disagreement as to whether the position taken by the Home Office is correct. It has been reported that the president and chief scientist of the Royal Pharmaceutical Society have written to the Home Office asking it to provide clear guidance on the steps that pharmacists should be taking to ensure that they abide by the law in respect of CBD oils, in light of reports that have been circulating suggesting that CBD oil products with a THC content of less than 0.2% are legal and by implication that they may not require a Home Office licence (these reports may be based on the interpretation of the regulations relating to the cultivation and importation of low THC industrial hemp).

Even if a CBD-containing product is not subject to the controls of the Act or the Regulations, the UK’s medicines and medical devices regulator, the Medicines & Healthcare products Regulatory Agency (MHRA), has taken the view that “products containing cannabidiol (CBD) used for medical purposes are a medicine” and as such must have an MHRA product licence (marketing authorisation) before being made available to consumers, supplied or advertised unless they fall under the narrow exemptions of the Human Medicines Regulations 2012 (the exemptions now include CBPMs, subject to certain controls). To date, only one cannabis-based medicinal product, Sativex, (for the treatment of multiple sclerosis) has been licensed by the MHRA.

CBPMs

The Regulations define a CBPM as a preparation or product that

(a) is or contains cannabis, cannabis resin, cannabinol or a cannabinol derivative (not being dronabinol or its stereoisomers);

(b) is produced for medicinal use in humans; and

(c) is

(i) a medicinal product, or

(ii) a substance or preparation for use as an ingredient of, or in the production of an ingredient of, a medicinal product[.]

A limited number of substances are excepted from the definition, including Sativex (as a licensed product) and synthetic dronabinol. Only if a cannabis product meets the requirements above will it be considered a CBPM – otherwise, it will be treated as a Schedule 1 drug under the Regulations; that is, a drug that has no known legitimate medical uses and that can generally be used only for research under a Home Office licence.

While allowing unlicensed cannabis-based products to be prescribed for medicinal purposes, the recent amendments to the Regulations set out restrictions relating to the supply of CBPMs. Where CBPMs are unlicensed i.e. they have not obtained a marketing authorisation from the MHRA, a prescription for a CBPM can be written only by a specialist doctor on the General Medical Council’s Specialist Register and in accordance with the regulations applying to “special medicinal products”. If a CBPM receives a marketing authorisation from the MHRA, it will cease to be a “special medicinal product” and can be prescribed by other qualified practitioners.

Further, entities in the CBPM’s supply chain must be licensed by the Home Office and MHRA. For example, importers must have a Home Office import and domestic licence and manufacturers must have a domestic licence and an MHRA dealer’s or manufacturer’s licence to supply and possess CBPMs. Wholesale distributors must also be licensed. Cultivation of cannabis also requires a Home Office licence. In addition, there are import notifications, records, storage and labelling requirements with which importers, manufacturers and wholesalers must comply. Doctors prescribing CBPMs need to be confident that the actual supply of the CBPM they prescribe is lawful.

In addition, CBPMs can be prescribed by doctors only when there is clear published evidence of benefit or UK Guidelines (which have not yet been published), and only to patients whose established treatment options have been exhausted.

The public health minister said that as of May 2019, only six NHS prescriptions had been written since the changes to the Regulations came into effect and ten private prescriptions were written between January 2019 and February 2019 according to the NHS Business Services Authority, which collects data on primary care. No data is available regarding prescriptions written in respect of secondary care.

Novel Foods Regulation

EU Regulation 2015/2283 of the European Union (the Novel Foods Regulation) regulates “novel foods”. A novel food is “any food that was not used for human consumption to a significant degree within the Union before 15 May 1997”. Under EU law, in the interests of safeguarding public health, novel foods must undergo a safety assessment before they can be authorised for placing on the market. On 17 January 2019, a new entry for cannabinoids was added to the Novel Food Catalogue (a non-legally binding guide in which the EU makes recommendations to member states as to whether a product is likely to require authorisation under the Novel Foods Regulation). The entry provides that “products containing cannabinoids are considered novel foods as a history of consumption has not been demonstrated”. However, seeds, seed oil, hemp seed flour and defatted hemp seed are not deemed to be novel foods unless cannabinoids have been added to them.

It is now up to EU member states to determine whether CBD products require authorisation in order to be marketed in the relevant member state. However, member states are often influenced by the fact that a food has been listed in the Novel Food Catalogue, so it seems likely that many products will now be treated as novel foods that require authorisation. The Food Standards Agency, the UK’s regulatory body in charge of food safety, has said that it accepts the EU’s clarification that CBD extracts are novel foods and that it is “committed to finding a proportionate way forward by working with local authorities, businesses and consumers to clarify how to achieve compliance in a marketplace in a proportionate manner”. Accordingly, in England, local authorities will have the power under the Novel Foods (England) Regulations 2018 to seize and inspect suspected unauthorised novel foods and issue compliance and stop notices requiring a product to be removed from sale – for instance, when there is reason to suspect it could be harmful to consumers – and to impose fines. The European Food Standards Agency, which is responsible for food safety in the European Union, is currently considering the first novel food application for CBD.

Best practices

This is a constantly evolving and complex area of law. The best practice is to obtain qualified legal advice specific to your circumstances, as licensing mistakes can have costly and even criminal repercussions.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions